3.9 Klinischer Stellenwert eines neuen 3-Generations-Thyreoglobulin (TG)-immunoradiometrischen-Assays (IRMA) in der Nachsorge des differenzierten Schilddrüsenkarzinoms

How reliable is secondary risk stratification with stimulated thyroglobulin in patients with differentiated thyroid carcinoma?

“…In order to increase NPV of sTg testing, Pacini et al recommended combination of sTg testing (NPV alone: 85%) with cervical ultrasound (combined NPV: 99%) (15). Although sTg-negative recurrence has become a rare condition, ultrasound is the most sensitive diagnostic procedure for early detection and should therefore be performed (18).…”

“…For RIT and follow-up, each contact was documented. Beside laboratory findings -(s)Tg, TSH, FT3,FT4, Anti-Tg antibodies, serum calcium and phosphate, parathormone, urinary iodine -and the results of cervical sonography (Hitachi EUB-420, Hitachi, Wiesbaden, Germany, fitted with a 7.5 MHz and a 10 MHz transducer), we documented therapeutic decisions, medical therapy, including vitamin D therapy, use of recombinant human thyreoidea stimulating hormone (rhTSH), and the results of imaging methods ( 131 I or 123 I-scintigraphy, 18 F-fluorodesoxyglucose [FDG] positron emission tomography [PET] and FDG-PET combined with computed tomography [PET-CT], multi-slice-CT and magnetic resonance imaging [MRI]).…”